Second and third line treatment in non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 2, 2009, Pages 117-126

  Favaretto, Adolfo ^a   Pasello, Giulia ^a   Magro, Cristina ^a   Schettino, Clorinda ^b   Gridelli, Cesare ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

Docetaxel; NSCLC; Pemetrexed; Second line; Targeted therapies

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; SAGOPILONE; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VINFLUNINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERTENSION; HYPOXIA; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MONOTHERAPY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; SALVAGE THERAPY;

EID: 67649576696     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.01.009     Document Type: Review

References (69)

1. Goldstraw P., Crowley J., Chansky K., et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumours. J Thorac Oncol 2 (2007) 706-714
2. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
3. Fossella F.V., De Vore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced NSCLC previously treated with platinum-containing regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
4. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
5. Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
6. Kim E.S., Hirsch V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372 (2008) 1809-1818
7. Gridelli C., Gallo C., Di Maio M., et al. A randomized clinical trial of two docetaxel regimens (weekly versus 3-week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
8. Schuette W., Nagel S., Blankenburg T., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 (2005) 8389-8395
9. Camps C., Massuti B., Jimenez A., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006) 467-472
10. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomized trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced NSCLC. Ann Oncol 16 (2005) 90-96
11. Di Maio M., Perrone F., Chiodini P., et al. Individual patients data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced NSCLC. J Clin Oncol 25 (2007) 1377-1382
12. Bria E., Cuppone F., Ciccarese M., et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 32 (2006) 583-587
13. Pujol J.L., Paul S., Chouaki N., et al. Survival without common toxicity criteria grade 3-4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 212 (2007) 710-716
14. De Marinis F., Pereira J.R., Fossella F., et al. Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 30-36
15. Cullen M.H., Zatloukal P., Sorenson S., et al. Pemetrexed for the treatment of advanced NSCLC: results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy. J Thorac Oncol 2 Suppl. 4 (2007) S316-S317
16. Weiss G.J., Langer C., Rosell R., et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 4405-4411
17. Zinner R., Fossella F.V., Kies M.S., et al. A phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced NSCLC. J Clin Oncol 25 18 (Suppl.) (2007) 18149
18. Bearz A., Garassino I., Cavina R., et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 60 (2008) 240-245
19. 2 in a randomized phase II study for pretreated patients, with locally advanced or metastatic NSCLC. J Thorac Oncol 2 Suppl. 4 (2007) S681
20. Peterson P., Park K., Fossella F., Gatzemeier U., John W., and Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced NSCLC. J Thorac Oncol 2 Suppl. 4 (2007) S851
21. Crinò L., Mosconi A.M., Scagliotti G., et al. Gemcitabine as second line treatment for advanced non small cell lung cancer: a phase II trial. J Clin Oncol 17 (1999) 2081-2085
22. Rossi D., Catalano V., Alessandroni P., et al. A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non-small-cell lung cancer. Clin Lung Cancer 8 (2007) 382-385
23. Berghmans T., Lafitte J.J., Lecomte J., et al. Second-line paclitaxel in non-small-cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer 96 (2007) 1644-1649
24. Georgoulias V., Kouroussis C., Agelidou A., et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomized, phase II study. Br J Cancer 91 (2004) 482-488
25. Kosmas C., Tsavaris N., Syrigos K., et al. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small-cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol 59 (2007) 51-59
26. Georgoulias V., Agelidou A., Syrigos K., et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomized phase II study. Br J Cancer 93 (2005) 763-769
27. Takiguchi Y., Moriya T., Asaka-Amano Y., et al. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small-cell lung cancer. Lung Cancer 58 (2007) 253-259
28. Grossi F., Fasola G., Rossetto C., et al. Phase II study of irinotecan and docetaxel in patients with previously treated NSCLC: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer 52 (2006) 89-92
29. Wachters F.M., Groen H.J., Biesma B., et al. A randomized phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIB-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 (2005) 15-20
30. Pectasides D., Pectasides M., Farmakis D., et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced NSCLC: a randomized phase II trial. Ann Oncol 16 (2005) 294-299
31. Molina J.R., Nikcevich D., Hillman S., et al. A phase II NCCTG study of irinotecan and docetaxel in previously treated patients with NSCLC. Cancer Invest 24 (2006) 382-389
32. Lilenbaum R., Socinski M.A., Altorki N.K., et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of NSCLC. J Clin Oncol 24 (2006) 4825-4832
33. Cobo M., Gutierrez V., Alcaide J., et al. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced NSCLC and good performance status. Lung Cancer 56 (2007) 255-262
34. Vàzquez S., Huidobro G., Amenedo M., et al. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anticancer Drugs 18 (2007) 1201-1206
35. Androulakis N., Kouroussis C., Kakolyris S., et al. Salvage treatment with paclitaxel and gemcitabine for patients with NSCLC after cisplatin-or-docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9 (1998) 1127-1130
36. Iaffaioli R.V., Tortoriello A., Gravina A., et al. Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small-cell lung cancer. Lung Cancer 30 (2000) 203-210
37. Mori K., Kamiyama Y., Kondo T., Kano Y., and Kodama T. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small-cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol 60 (2007) 189-195
38. Kobayashi T., Koizumi T., Urushihata K., et al. Phase II trial of biweekly gemcitabine and paclitaxel as second-line chemotherapy for patients with NSCLC previously treated with platinum-based chemotherapy. J Thorac Oncol 2 8 (Suppl. 4) (2007) S680
39. Maeng C.H., Lee J.J., Baek S.K., et al. Gemcitabine and vinorelbine combination as second-line therapy in previously taxane and platinum-treated non-small-cell lung cancer. J Thorac Oncol 2 8 (Suppl. 4) (2007) S684
40. Lopes G., Alencar A., Blaya M., et al. Gemcitabine and oxaliplatin as second and third line therapy of advanced and metastatic NSCLC: evidence of clinical activity and improvement in quality of life. J Thorac Oncol 2 8 (Suppl. 4) (2007) S683
41. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
42. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
43. Byoung C.C., Chong-Kun I., Moo-Suk P., et al. Phase II study of erlotinib in advanced NSCLC after failure of gefitinib. J Clin Oncol 25 (2007) 2528-2533
44. Grossi F., Brianti A., Defferrari C., et al. Gefitinib treatment outcome after progression on Erlotinib in patients with advanced NSCLC. Eur J Cancer Suppl 5 4 (2007) 395 [P #6625]
45. Gridelli C., Maione P., Amoroso D., et al. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit Rev Oncol Hematol 66 (2008) 155-162
46. Kim E.S., Mauer A.M., Tran H.T., et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced NSCLC: final report. Proc ASCO 22 (2003) [Abstr. 2581]
47. Hanna N., Lilenbaum R., Ansari R., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 (2006) 5253-5258
48. Herbst R.S., Johnson D.H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent NSCLC. J Clin Oncol 23 (2005) 2544-2555
49. Herbst R.S., O'Neill V.J., Fehrenbacher L., et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25 (2007) 4743-4750
50. Weiss G.J., Zeng C., Kelly K., Tran Z.V., and Bun P.A.J. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer 8 (2007) 335-338
51. Govindan R., Brahmer J.R., Novello S., et al. Phase II study investing the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small-cell lung cancer (NSCLC). Eur J Cancer Suppl 5 4 (2007) 365
52. Socinski M.A., Novello S., Brahmer J.R., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26 4 (2008) 650-656
53. Adjei A.A., Molina J.R., Hillman S.L., et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 25 18S (Suppl.) (2007) 7547
54. Gatzemeier U., Blumenschein G., Fossella F., et al. Phase II trial of single-agent sorafenib in patients with advanced non-small-cell lung carcinoma. J Clin Oncol 24 June (18S) (Suppl). (2006) 7002
55. Blumenschein Jr. G.R., Robert F., Melnyk O., et al. Phase II study of erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small-cell lung cancer (NSCLC). Eur J Cancer Suppl 5 4 (2007) 359
56. Groen H.J.M., Baas P., Kennedy S.J., and Langmuir P. Vandetanib in advanced NSCLC: an ongoing clinical evaluation programme. Eur J Cancer Suppl 5 (2007) 390 [P #6609]
57. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated NSCLC. J Clin Oncol 25 (2007) 4270-4277
58. Vansteenkiste J., Lara P.N., Le Chevalier T., et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with NSCLC whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25 (2007) 3448-3455
59. Gatzemeier U., von Pawel J., Eschbach C., et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. Eur J Cancer Suppl 5 4 (2007) 378
60. Abrey L., Wen P.Y., Govindan R., et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with NSCLC: an open-label, multicenter, phase II study. J Clin Oncol 25 18S (Suppl.) (2007) 18058
61. Yee L., Lynch T., Villalona-Calero M., et al. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol 23 16S (2005) 7127
62. Ravaioli A., Papi E., Pasquini M., et al. Lipoplatin monotherapy: a phase II trial in second-line treatment of metastatic non-small-cell lung cancer. J Clin Oncol 25 18S (Suppl.) (2007) 18160
63. Douillard J.Y., Coudert B., Gridelli C., et al. Phase III study of IV vinflunine versus IV docetaxel in patients (pts) with advanced or metastatic NSCLC previously treated with a platinum-containing regimen. Eur J Cancer Suppl 5 4 (2007) 358
64. Ramlau R., Gervais R., Krzakowski M., et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small cell lung cancer. J Clin Oncol 24 (2006) 2800-2807
65. Burris H., Krug L., Shapiro G., et al. SNS-595: preliminary results of two phase II second-line studies in lung cancer. Eur J Cancer Suppl 5 4 (2007) 371-372 [P #6547]
66. Choong N.W., Mauer A.M., Hoffman P.C., et al. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced NSCLC. J Thorac Oncol 1 (2006) 245-251
67. Charpidou A.G., Zalonis A., Katirtzoglou E., et al. A phase II study of carboplatin plus pemetrexed in previously treated patients with non-small-cell lung cancer (NSCLC). J Thorac Oncol 2 8 (Suppl. 4) (2007) S669
68. Feliu J., Martin G., Castro J., et al. Docetaxel and mitomycin as second-line treatment in advanced NSCLC. Cancer Chemother Pharmacol 58 (2006) 527-531
69. Babiak A., Hetzel J., Godde F., et al. Mitomycin C and vinorelbine for second-line chemotherapy in NSCLC-a phase II trial. Br J Cancer 96 (2007) 1052-1056